The CEO of Abyan Pharmed Co. announced a substantial reduction in international payments needed to import medications, thanks to the company’s manufacturing of neurological products.
“We realized such a decrease by our initial product portfolio only,” Dr. Sara Sepehr told the GPI’s PR unit. “Significant further reduction will ensue when our other products hit the Iranian medication market. As a GPI subsidiary, we have already marketed several specialty medications such as anti-depressants, Parkinson and epilepsy medications, and food/dietary supplements.”
“Our team has focused on producing central nervous system (CNS) medications. Our cardiovascular, gastrointestinal, hair and skin, and anti-cancer medications will hit the market soon”, the CEO pointed out.
